Which antibiotics are non‑cardiotoxic and do not cause QT‑interval prolongation, arrhythmia, or cardiomyopathy?

Non-Cardiotoxic Antibiotics

Penicillins and cephalosporins are the safest non-cardiotoxic antibiotic options that do not cause QT-interval prolongation or arrhythmias and should be preferentially selected when clinically appropriate. 1

Safe Antibiotic Classes

The 2023 Canadian Cardiovascular Society guidelines explicitly identify penicillins and cephalosporins as safe alternatives that do not affect the QTc interval 1. These should be your first-line choices when:

• The patient is already taking a QT-prolonging medication
• The patient has baseline QTc prolongation
• The patient has risk factors for arrhythmia (elderly, female, structural heart disease, electrolyte abnormalities)

High-Risk Cardiotoxic Antibiotics to Avoid

The following antibiotics carry significant cardiotoxic risk and should be avoided when safer alternatives exist:

Macrolides (in descending order of risk):

• Erythromycin - highest risk 1
• Clarithromycin
• Azithromycin - lowest macrolide risk but still carries risk 1
  • Note: Azithromycin shows increased cardiac event risk (OR 1.40) specifically when combined with other QT-prolonging drugs 2

Fluoroquinolones (quinolones):

• All fluoroquinolones prolong QT 1
• Moxifloxacin is used as a positive control in QT studies due to its reliable QT-prolonging effect 3

Other high-risk antibiotics:

• Linezolid (ROR 12.41 for TdP/QTP) 4
• Amikacin (ROR 11.80 for TdP/QTP) 4
• Imipenem-cilastatin (ROR 6.61 for TdP/QTP) 4

Moderate-Risk Antibiotics

Penicillin combinations and ceftriaxone show statistically significant but lower associations with QT prolongation (ROR 3.42 and 2.55 respectively) 4. While technically associated with some risk, they remain far safer than macrolides and fluoroquinolones.

Novel Safe Option

Ketolide antibiotics (e.g., solithromycin) represent a structural modification of macrolides that eliminates QT-prolonging effects. Unlike traditional macrolides, solithromycin demonstrated no clinically meaningful QT prolongation with a slightly negative slope of -0.86 ms per ng/mL 3, 5. When a macrolide-spectrum antibiotic is required in high-risk patients, consider a ketolide if available.

Clinical Decision Algorithm

When selecting antibiotics in patients with cardiac risk:

1. First choice: Penicillins or cephalosporins (if clinically appropriate for the infection)

2. If macrolide/fluoroquinolone coverage needed:

   • Reassess if truly necessary
   • Consider ketolide alternatives 5
   • If unavoidable, use azithromycin over erythromycin 1

3. Before prescribing any potentially cardiotoxic antibiotic, check:

   • Current medications for other QT-prolonging drugs
   • Baseline QTc if risk factors present
   • Electrolytes (K+, Mg++, Ca++) 1

4. Avoid combination therapy with multiple QT-prolonging agents - the risk is multiplicative, not additive 2

Important Caveats

The pneumonia severity paradox: In hospitalized community-acquired pneumonia patients, QT prolongation occurs frequently (72.1% of patients) regardless of antibiotic choice, driven by illness severity rather than antibiotic selection 6. Higher pneumonia scores and previous stroke independently predict pathological QTc 6. This doesn't negate antibiotic cardiotoxicity but emphasizes that critically ill patients develop QT prolongation from multiple factors.

Risk stratification matters: The absolute risk of TdP remains low even with high-risk antibiotics in otherwise healthy patients. However, when risk factors accumulate (female sex, age >65, structural heart disease, electrolyte abnormalities, concurrent QT-prolonging drugs), the risk becomes clinically significant 1, 4.

Resource for checking: Direct patients and providers to www.crediblemeds.org for comprehensive, updated lists of QT-prolonging medications 1.